GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » DuChemBio Co Ltd (XKRX:176750) » Definitions » Debt-to-EBITDA

DuChemBio Co (XKRX:176750) Debt-to-EBITDA : 1.95 (As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is DuChemBio Co Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

DuChemBio Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₩14,726 Mil. DuChemBio Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₩7,030 Mil. DuChemBio Co's annualized EBITDA for the quarter that ended in Dec. 2023 was ₩11,175 Mil. DuChemBio Co's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was 1.95.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for DuChemBio Co's Debt-to-EBITDA or its related term are showing as below:

XKRX:176750' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -17.43   Med: 3.19   Max: 6.67
Current: 1.95

During the past 8 years, the highest Debt-to-EBITDA Ratio of DuChemBio Co was 6.67. The lowest was -17.43. And the median was 3.19.

XKRX:176750's Debt-to-EBITDA is ranked worse than
53.25% of 661 companies
in the Drug Manufacturers industry
Industry Median: 1.7 vs XKRX:176750: 1.95

DuChemBio Co Debt-to-EBITDA Historical Data

The historical data trend for DuChemBio Co's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DuChemBio Co Debt-to-EBITDA Chart

DuChemBio Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial -5.42 -14.70 6.16 4.44 1.95

DuChemBio Co Semi-Annual Data
Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial -5.42 -14.70 6.16 4.44 1.95

Competitive Comparison of DuChemBio Co's Debt-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, DuChemBio Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


DuChemBio Co's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, DuChemBio Co's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where DuChemBio Co's Debt-to-EBITDA falls into.



DuChemBio Co Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

DuChemBio Co's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(14725.659 + 7029.692) / 11175.316
=1.95

DuChemBio Co's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(14725.659 + 7029.692) / 11175.316
=1.95

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is one times the quarterly (Dec. 2023) EBITDA data.


DuChemBio Co  (XKRX:176750) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


DuChemBio Co Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of DuChemBio Co's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


DuChemBio Co (XKRX:176750) Business Description

Traded in Other Exchanges
N/A
Address
Daegu 47, Jinyang Building, 4th floor, Chungjeong-ro 2, Gyeonggi, Seoul, KOR, 190-3
DuChemBio Co Ltd is engaged in manufacturing and sale of radiopharmaceuticals and radioactive medicines. It also imports and sells medical equipment related to nuclear medicines.

DuChemBio Co (XKRX:176750) Headlines

No Headlines